Astrazeneca (AZN) EPS (Weighted Average and Diluted) (2009 - 2025)

Astrazeneca's EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $1.49 for Q4 2025.

• In Q4 2025, EPS (Weighted Average and Diluted) rose 55.21% year-over-year to $1.49; the TTM figure through Dec 2025 stood at $5.64 (up 25.06% YoY), while the FY2025 annual figure was $6.54, up 45.33% from the prior year.
• EPS (Weighted Average and Diluted) was $1.49 for Q4 2025 at Astrazeneca, down from $1.62 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.62 in Q3 2025 to a low of $0.22 in Q4 2021.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.94 across 5 years, with a median of $0.96 in 2024.
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) tumbled 73.19% in 2022, then soared 408.7% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.22 in 2021, then jumped by 163.64% to $0.58 in 2022, then gained by 6.9% to $0.62 in 2023, then jumped by 54.84% to $0.96 in 2024, then jumped by 55.21% to $1.49 in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.49 (Q4 2025), $1.62 (Q3 2025), and $1.57 (Q2 2025), per Business Quant data.